Ocugen to Present at World Orphan Drug Congress USA 2020 Conference
MALVERN, Pa., July 21, 2020 – Ocugen (NASDAQ: OCGN) announced its participation in the World Orphan Drug Congress USA 2020, scheduled virtually from August 24-27, 2020. Rasappa Arumugham, PhD, Chief Scientific Officer, will present on Ocugen's modifier gene therapy platform during the Next Generation Therapies Seminar on August 24 at 1:00 PM ET. This platform aims to treat retinal diseases with a single drug, enhancing therapeutic options for conditions like wet age-related macular degeneration and diabetic retinopathy.
- None.
- None.
MALVERN, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at the World Orphan Drug Congress USA 2020 Conference, to be held virtually from August 24-27, 2020.
Rasappa Arumugham, PhD, Chief Scientific Officer of Ocugen, will highlight Ocugen’s breakthrough modifier gene therapy platform as part of the Next Generation Therapies Seminar.
Presentation Details:
Date: Monday, August 24, 2020
Time: 1:00 PM (Eastern Time)
Website: https://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat rare and underserved eye diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. For more information, please visit https://ocugen.com/
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
Corporate Contact: Ocugen, Inc. Sanjay Subramanian Chief Financial Officer Media Contact: LaVoieHealthScience Emmie Twombly +1 857-389-6042
FAQ
What is Ocugen presenting at the World Orphan Drug Congress 2020?
When is Ocugen's presentation at the World Orphan Drug Congress?
What potential diseases does Ocugen's gene therapy target?
Where can I find more information about Ocugen?
What is the focus of Ocugen, Inc.?
